About Contact Us Careers

Phenylketonuria Drugs Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 3031
Published Date: Dec 24, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Phenylketonuria Treatment Landscape

Ultragenyx Pharmaceutical
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
PTC Therapeutics
BioMarin
Homology Medicines, Inc.
SOM BIOTECH
Nestle Health Science
American Gene Technologies Inc.
Rubius Therapeutics, Inc.
Synlogic

Browse Key Market Insights with Data Illustration:

Phenylketonuria Treatment Market Size | Growth Report 2037

In the News

Author Credits: Radhika Pawar

Report ID: 3031
Published Date: Dec 24, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of phenylketonuria treatment is evaluated at USD 843.44 million.

Phenylketonuria Treatment Market size was valued at USD 794.16 million in 2024 and is set to exceed USD 1.98 billion by 2037, expanding at over 7.3% CAGR during the forecast period i.e., between 2025-2037.

North America industry is likely to hold largest revenue share by 2037, attributed to rising research and development activities for novel drugs, coupled with favourable government regulations for the treatment of phenylketonuria.

The major players in the market are Ultragenyx Pharmaceutical, PTC Therapeutics, BioMarin, Homology Medicines, Inc., SOM BIOTECH, Nestle Health Science, American Gene Technologies Inc., Rubius Therapeutics, Inc., Synlogic, and others.

Inquiry Before Buying Request Free Sample